BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18980043)

  • 1. An oral contraceptive with 3 approved indications.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):717-9. PubMed ID: 18980043
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
    Dickerson V
    J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new extended regimen for the management of premenstrual symptoms needs to be properly assessed.
    Marasinghe JP; Don CK; Amarasinghe AA
    Am J Obstet Gynecol; 2007 Oct; 197(4):436; author reply 436-7. PubMed ID: 17904994
    [No Abstract]   [Full Text] [Related]  

  • 5. YAZ and the novel progestin drospirenone.
    Mishell DR
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Extracontraceptive benefits of EE/DRSP (Yaz) in 24+4 day regimen].
    Bruni Bresciani V
    Minerva Ginecol; 2010 Jun; 62(3):261-6. PubMed ID: 20595950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 μg plus drospirenone 3mg administered in a 24/4 regimen: a pooled analysis.
    Koltun W; Maloney JM; Marr J; Kunz M
    Eur J Obstet Gynecol Reprod Biol; 2011 Apr; 155(2):171-5. PubMed ID: 21288628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the treatment of acne.
    Kimball AB
    J Reprod Med; 2008 Sep; 53(9 Suppl):742-52. PubMed ID: 18980046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
    Coffee AL; Kuehl TJ; Willis S; Sulak PJ
    Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
    Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
    Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAZ in the treatment of premenstrual dysphoric disorder.
    Rapkin AJ
    J Reprod Med; 2008 Sep; 53(9 Suppl):729-41. PubMed ID: 18980045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an oral contraceptive containing drospirenone in an extended regimen.
    Sillem M; Schneidereit R; Heithecker R; Mueck AO
    Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Less estrogen in new oral contraceptive.
    Am J Nurs; 2003 Apr; 103(4):111-2. PubMed ID: 12677126
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone/ethinylestradiol: a review on efficacy and noncontraceptive benefits.
    Machado RB; Pompei Lde M; Giribela AG; Giribela CG
    Womens Health (Lond); 2011 Jan; 7(1):19-30. PubMed ID: 21175386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium.
    Rapkin RB; Creinin MD
    Expert Opin Pharmacother; 2011 Oct; 12(15):2403-10. PubMed ID: 21877996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.